CASI Pharmaceuticals (CASIF) Accumulated Expenses (2021 - 2025)

CASI Pharmaceuticals (CASIF) has 5 years of Accumulated Expenses data on file, last reported at $3.7 million in Q4 2025.

• Quarterly Accumulated Expenses rose 10.32% year-over-year to $3.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.7 million (up 10.32% YoY) and the FY2025 annual result came in at $3.7 million, up 10.32% from the prior year.
• Accumulated Expenses eased to $3.7 million in Q4 2025, from $20.0 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $14.0 billion in Q1 2025 to a low of $3.3 million in Q4 2024.
• A 5-year average of $4.1 billion and a median of $18.2 million in 2025 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2024 — Accumulated Expenses slumped 99.97% — and 2025, when it jumped 176083.9%.
• Tracing CASIF's Accumulated Expenses over 5 years: stood at $3.3 million in 2021, then soared by 254.2% to $11.8 million in 2022, then surged by 103894.58% to $12.3 billion in 2023, then tumbled by 99.97% to $3.3 million in 2024, then climbed by 10.32% to $3.7 million in 2025.
• The last three Accumulated Expenses figures came in at $3.7 million (Q4 2025), $20.0 million (Q3 2025), and $18.2 million (Q2 2025), per Business Quant data.